The value of early treatment in patients with haemophilia and inhibitors (original) (raw)
Current and evolving features in the clinical management of haemophilia
Anna Cerbone
Blood transfusion = Trasfusione del sangue, 2014
View PDFchevron_right
Special lectures in haemophilia management
Angelika Batorova
Haemophilia, 2010
View PDFchevron_right
Development of inhibitors in haemophilia. Ongoing epidemiological study
L. Ritli, Margit Serban
Hämostaseologie, 2011
View PDFchevron_right
Management of haemophilia
Paul Giangrande
Paediatrics and Child Health, 2011
View PDFchevron_right
Development of inhibitors in haemophilia
Emilia Ursu
Hämostaseologie, 2011
View PDFchevron_right
The need for speed in the management of haemophilia patients with inhibitors
Ivo V Elezovic
Haemophilia, 2011
View PDFchevron_right
Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain
Carlos Aguilar
Blood Coagulation & Fibrinolysis, 2008
View PDFchevron_right
Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A
minke twijnstra
Haemophilia, 2001
View PDFchevron_right
Emerging and receding risks of therapeutic regimens for haemophilia
Albert Farrugia
Haemophilia, 2004
View PDFchevron_right
The socio-economic burden of patients affected by Hemophilia with inhibitors
Giacomo Crotti
European Journal of Haematology, 2018
View PDFchevron_right
Present and future challenges in the treatment of haemophilia: The patient's perspective
Lorenzo G Mantovani
2013
View PDFchevron_right
Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres
G. Auerswald, Carmen Altisent
Haemophilia, 2007
View PDFchevron_right
Advancement in the treatment of haemophilia
Rahul kr Bhardwaj
International journal of biological macromolecules, 2018
View PDFchevron_right
Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience
Diane J Nugent
Haemophilia, 2007
View PDFchevron_right
Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study
Karin Fijnvandraat
British Journal of Haematology
View PDFchevron_right
Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study
FRANCESCO DEMARTIS
Haemophilia, 2017
View PDFchevron_right
Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies
Amanda Bok
Haematologica, 2020
View PDFchevron_right
Long-term safety and efficacy of recombinant activated factor VII (NovoSeven) in haemophilia patients with inhibitors: interim post marketing study analysis of 5 patient exposure years
Masashi Taki
Japanese Journal of Thrombosis and Hemostasis, 2006
View PDFchevron_right
Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy
Namrata Punit Awasthi
Therapeutic Advances in Hematology, 2018
View PDFchevron_right
Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients
Silva Zupančić Šalek
European Journal of Haematology, 2018
View PDFchevron_right
European principles of inhibitor management in patients with haemophilia
Alison Dougall
Orphanet Journal of Rare Diseases, 2018
View PDFchevron_right
Inhibitors in haemophilia A: current management and open issues
N. Cabrera
Haemophilia, 2007
View PDFchevron_right
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report
Angelika Batorova
Haemophilia, 2010
View PDFchevron_right
Single-dose (270 μg kg −1 ) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres
Andrzej Mital
Haemophilia, 2009
View PDFchevron_right
A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey
Doğukan Yılmaz
Journal of Medical Economics, 2005
View PDFchevron_right
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic
U. Hedner
Haemophilia, 2009
View PDFchevron_right
Inhibitors in nonsevere haemophilia A: outcome and eradication strategies
Karin Fijnvandraat
Thrombosis and haemostasis, 2015
View PDFchevron_right
Use of recombinant factor VIIa (NovoSeven) in a haemophilia A patient with inhibitor in Kuwait
wahib abdul
Haemophilia, 1999
View PDFchevron_right
Frequency of Specific and Non-specific Inhibitors in Haemophilia A Patients
Dr. Munira Borhany, Javeria Ashfaq
View PDFchevron_right
Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment
R. Schutgens
Haemophilia, 2009
View PDFchevron_right
Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology
Melen Brinza
Annals of translational medicine, 2021
View PDFchevron_right
The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients
Kanjaksha Ghosh
Indian Journal of Hematology and Blood Transfusion, 2014
View PDFchevron_right
Inhibitor Screening for Patients With Hemophilia In Turkey
Sabri KEMAHLI
View PDFchevron_right